Induced pluripotent stem cell-derived 'disease-in-a-dish' models have propelled neurological drugs from Bristol-Myers Squibb, GlaxoSmithKline and Roche into clinical trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Inborn errors of metabolism: Lessons from iPSC models
Reviews in Endocrine and Metabolic Disorders Open Access 09 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Stem-cell discovery platforms yield first clinical candidates. Nat Rev Drug Discov 14, 589–591 (2015). https://doi.org/10.1038/nrd4708
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4708
This article is cited by
-
Inborn errors of metabolism: Lessons from iPSC models
Reviews in Endocrine and Metabolic Disorders (2021)
-
Tau-based therapies in neurodegeneration: opportunities and challenges
Nature Reviews Drug Discovery (2017)
-
Induced pluripotent stem cell technology: a decade of progress
Nature Reviews Drug Discovery (2017)
-
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Nature Reviews Cardiology (2016)